Pharmaceutical Product Development, Inc. Merger Litigation (Nasdaq: PPDI)
Law Office of Brodsky & Smith, LLC Announces Investigation of Pharmaceuticals Product Development, Inc.
BALA CYNWYD – (BUSINESS WIRE) Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Pharmaceuticals Product Development, Inc. (“PPD” or the “Company”) (Nasdaq: PPDI - News) relating to the proposed acquisition by an affiliate of The Carlyle Group and Hellman & Friedman.
Under the terms of the offer PPD shareholders would receive $33.25 in cash for each share PPD stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of PPD for not acting in the Company’s shareholders' best interests in connection with the sale process. The transaction may undervalue the Company as an analyst has set a price target of $38.00 per PPD share.
If you own shares of PPD stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at firstname.lastname@example.org, or by calling toll free 877-LEGAL-90.
To Join the Pharmaceutical Product Development, Inc. Litigation
Fill out this form
The complaint is unavailable at this time